Veritable’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Veritable’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,835	Closed	-$226K	–	940
2022 Q2	$226K	Sell	2,835 -297	-9%	-$28.1K	﹤0.01%	773
2022 Q1	$330K	Sell	3,132 -154	-5%	-$15K	0.01%	686
2021 Q4	$354K	Sell	3,286 -1,203	-27%	-$131K	0.01%	667
2021 Q3	$492K	Sell	4,489 -262	-6%	-$27.2K	0.01%	551
2021 Q2	$445K	Sell	4,751 -218	-4%	-$20.1K	0.01%	571
2021 Q1	$457K	Sell	4,969 -1,747	-26%	-$147K	0.01%	532
2020 Q4	$491K	Buy	6,716 +7	+0.1%	+$520	0.01%	499
2020 Q3	$521K	Sell	6,709 -886	-12%	-$61K	0.01%	456
2020 Q2	$422K	Sell	7,595 -684	-8%	-$29.3K	0.01%	503
2020 Q1	$245K	Sell	8,279 -62	-0.7%	-$2.1K	0.01%	619
2019 Q4	$302K	Buy	+8,341	New	+$256K	0.01%	677

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Veritable's HZNP Position: Q3 2022 in Review

Veritable sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 2,835 shares — an estimated $226K sold.

Veritable first reported a position in HZNP in Q4 2019 and held it in 11 quarters. The position peaked at $521K in Q3 2020. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Veritable reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Veritable sold 2,835 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $226K.
Veritable first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2019 and held it in 11 quarters.
Veritable's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $521K in Q3 2020.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Veritable's 13F filing for Q3 2022, filed 14 Nov 2022.